Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
04 Settembre 2024 - 7:30AM
UK Regulatory
Nicox Appoints Christine Placet to Board of Directors; Michele
Garufi steps down from Board
|
Press Release |
|
Nicox Appoints Christine Placet to Board of Directors; Michele
Garufi steps down from Board |
-
Christine Placet is CFO of Theranexus, and was formerly CEO
of Horama and Trophos
- Michele
Garufi, former Chairman and CEO of Nicox, hands over his Board
position after over more than 25 years at the company he
co-founded
- The
Nicox Board has now been entirely renewed to bring in the expertise
to support the Company’s strategic direction going
forward
September 4th,
2024 – release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, ALCOX), an
international ophthalmology company, today announced that Michele
Garufi is stepping down as a member of the Board of Directors. The
Board has appointed Christine Placet, a deeply experienced CEO and
financial leader in the biotech industry, as a new Board member.
The renewal of the Nicox Board brings the appropriate expertise to
support the Company’s strategic direction going forward.
“I am delighted to welcome Christine Placet to Nicox as a new
Board member. I had the pleasure of working with Christine during
our time at Trophos, where she played a pivotal role as CFO. Her
expertise, strategic vision, and leadership in biotech are
invaluable assets to Nicox. I look forward to working closely with
her again as we continue to drive the business forward, with the
focus on our de-risked compound NCX 470, moving towards topline
results from the second pivotal Phase 3 trial, Denali, in H2
2025,” said Damian Marron, Chairman of
Nicox.
“On behalf of the Board and of Nicox, past and present, I would
like to express my heartfelt gratitude to Michele Garufi for his
dedicated and unstinting service to the company. Nicox has
benefited from Michele’s vision, business acumen, scientific
expertise and leadership for nearly 30 years, as we have sought to
develop innovative solutions to help maintain vision and improve
ocular health. We all wish Michele the very best for the
future.”
Michele Garufi, Co-Founder of Nicox, who served as CEO and
Chairman until 2022 commented: “After many years of
service at Nicox, this is the right time to hand over to a new
generation of leadership. With Damian Marron appointed Chairman and
Gavin Spencer as CEO earlier this year, we have a talented and
dynamic leadership team in place who have led companies through
critical phases of development and executed major financial
transactions. I am therefore confident that Nicox is in very
capable hands. I wish them every further success as they aim to
deliver on the potential of NCX 470 to improve treatment of
glaucoma.”
Christine Placet joins Nicox with a distinguished career in the
biotech industry. She started as an auditor at Ernst & Young
and then built up extensive experience of financial leadership in
small- and medium- sized companies. In 2004, she joined the biotech
company Trophos as Chief Financial Officer, later becoming Chief
Executive Officer. Under her leadership, Trophos was acquired by
Roche for €470 million in 2015. She then became CEO of Horama (now
Coave Therapeutics) in 2016, successfully leading funding rounds
and advancing a key product into development. In 2021, she
transitioned into consulting and joined Theranexus as CFO in April
2024. She is a graduate of Kedge Business School.
|
|
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470
(bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye
drop, for lowering intraocular pressure in patients with open-angle
glaucoma or ocular hypertension. Nicox generates revenue from
VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch +
Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in
multiple geographies, including to Harrow, Inc. in the U.S., and
Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets.
Nicox, headquartered in Sophia Antipolis, France, is listed on
Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC
Healthcare index.
For more information www.nicox.com |
|
Analyst coverage |
H.C. Wainwright & Co Yi Chen New York, U.S. |
|
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
|
Contacts |
|
Nicox
Gavin Spencer
Chief Executive Officer
T +33 (0)4 97 24 53 00
communications@nicox.com |
Media / Investors
Sophie Baumont
Cohesion Bureau
+33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
|
Disclaimer |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.
Risks factors which are likely to have a material effect on Nicox’s
business are presented in section 3 of the “Rapport Annuel
2023” which is available on Nicox’s website
(www.nicox.com).
Finally, this press release may be drafted in the French and
English languages. If both versions are interpreted differently,
the French language version shall prevail. |
Nicox S.A.
Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste
Galois, 06410 Biot, France
T +33 (0)4 97 24 53 00 |
- EN_NewBoardMemberChristinePlacet_PR_FINAL
Grafico Azioni Nicox (EU:ALCOX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Nicox (EU:ALCOX)
Storico
Da Nov 2023 a Nov 2024
